Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) concerning whether a series of statements by Eagle Pharmaceuticals Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On February 25, 2016, Eagle Pharmaceuticals Chief Executive Officer made an announcement concerning the pending New Drug Application ("NDA") for the Company's anticoagulant drug KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2."

On March 18, 2016, Eagle Pharmaceuticals revealed that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" concerning the substances used in KANGIO™.

On this news, NASDAQ: EGRX shares dropped 18.96% on March 18, 2016.

Based in Woodcliff Lake, New Jersey, and founded in 2007 Eagle Pharmaceuticals Inc is engaged in developing and commercializing injectable products mainly in the critical care and oncology areas.

If you purchased shares of Eagle Pharmaceuticals Inc (NASDAQ: EGRX) on or before March 18, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185